Ipatasertib is a highly selective ATP-competitive small-molecule AKT inhibitor that showed activity in a broad range of cancer types, including prostate, breast, ovarian, colorectal, and non-small-cell lung cancers [45]. This evidence concerns the gene AKT1 and cancer.